Falsified Medicines: MHRA publishes Class 4 FMD Medicines Information
Recommendation
14-16 May 2025
Vienna / Schwechat, Austria
Two-day training + 1-day Airport tour at Vienna Airport in cooperation with DHL
Register now for ECA's GMP Newsletter
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via WDA(H) 50340 HMS Wholesale Limited. This license has since then been terminated.
In a Falsified Medicines Directive (FMD) Alert published 19 March 2020, the MHRA says that "the products do appear to be genuine with legitimate batch numbers. These products are thought to have been stolen from the legitimate supply chain in early 2019 and reintroduced into the supply chain between May and August 2019. This means that the correct transport and storage conditions cannot be guaranteed and while unlikely, could impact their effectiveness."
Only the batch numbers mentioned in appendix 1 of the PDF are within the scope of this alert. You can download the document here.
Related GMP News
23.04.2025MHRA Class 2 Recall due to Blister Pack Mislabeling
15.04.2025Falsified Medicinal Products: Swissmedic Intensifies Controls on International Trade
15.04.2025EMA's 3-Year Work Plan for GMDP Inspectors Working Group: What's Planned for GDP?
15.04.2025Two GDP Non-Compliance Reports published in March
15.04.2025Visit the DHL Vienna Airport Campus
15.04.2025Questions and Answers from the ECA Webinar "GDP Update 2025" - Part 1